Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2017 Dec 6;32(4):1048–1051. doi: 10.1038/leu.2017.346

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018, corrected publication 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

NSG SPARC mice reveal opposing effects of niche-derived SPARC in human leukemia. Percentage and immunophenotyping of hCD45⁺ cells in the bone marrow of WT and SPARC^HDR/HDR mice engrafted with 10⁶ MLL-AF9-expressing THP-1 cells (WT NSG n=3; SPARC KO n=2) analyzed 5 weeks post transplant (a), 10⁶ cells from a cytogenetically normal (CN) primary AML case (WT NSG n=4; SPARC KO n=4) analyzed 11 weeks post transplant (b) or 10⁵ cells from a BCP-ALL relapsed case (ALL-265; WT NSG n=4; SPARC KO n=5) analyzed 5 weeks post transplant (c). The data show a significantly increased leukemic burden in SPARC^HDR/HDR mice receiving THP-1 cells (a). In stark contrast, leukemic burden is dramatically decreased in SPARC^HDR/HDR mice receiving the primary CN-AML case or the relapsed BCP-ALL case (ALL-265) (b, c). Of note, additional THP-1 and BCP-ALL cases (ALL-199) are depicted in supplementary Figures 7 and 8. Each dot represents an independent mouse. Unpaired Student’s t-test, **P<0.01.